Synchron Raises $200 Million to Advance Brain-Computer Interface for Paralysis
Synchron has secured an additional $200 million in a series D funding round. The company plans to use this capital to scale its operations and speed up commercialization of its nonsurgical brain-computer interface (BCI) designed for people with paralysis.
Investment Details
Double Point Ventures led the round, joined by existing investors including Arch Ventures, Khosta Ventures, Bezos Expeditions, NTI, and Metis. Other participants were the Australian National Reconstruction Fund, T.Rx Capital, the Qatar Investment Authority, K5 Global, Protocol Labs, and IQT.
Funding Context and Industry Momentum
This round increases Synchron's total funding to $345 million amid growing interest in BCI technologies. Earlier this week, Precision Neuroscience announced a partnership with SCI Ventures—supported by the Christopher & Dana Reeve Foundation—to develop its Layer 7 Cortical Interface aimed at paralysis treatment.
Related Advances in BCI Technology
Last month, a study revealed that Science Corp.’s PRIMA BCI retinal implant restored partial vision in individuals with advanced age-related macular degeneration.
Synchron announced Thursday, Nov. that Double Point Ventures led the round alongside returning and new investors.
Author's summary: Synchron’s recent $200 million series D funding emphasizes strong investor confidence and growing momentum in the brain-computer interface field to improve paralysis treatment.